tiprankstipranks
Trending News
More News >
Lepu Biopharma Co. Ltd. Class H (HK:2157)
:2157
Hong Kong Market
Advertisement

Lepu Biopharma Co. Ltd. Class H (2157) Price & Analysis

Compare
2 Followers

2157 Stock Chart & Stats


Lepu Biopharma Co. Ltd. Class H News

2157 FAQ

What was Lepu Biopharma Co. Ltd. Class H’s price range in the past 12 months?
Lepu Biopharma Co. Ltd. Class H lowest stock price was HK$2.26 and its highest was HK$10.50 in the past 12 months.
    What is Lepu Biopharma Co. Ltd. Class H’s market cap?
    Lepu Biopharma Co. Ltd. Class H’s market cap is HK$17.49B.
      When is Lepu Biopharma Co. Ltd. Class H’s upcoming earnings report date?
      Lepu Biopharma Co. Ltd. Class H’s upcoming earnings report date is Apr 01, 2026 which is in 215 days.
        How were Lepu Biopharma Co. Ltd. Class H’s earnings last quarter?
        Lepu Biopharma Co. Ltd. Class H released its earnings results on Aug 20, 2025. The company reported HK$0.022 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.022.
          Is Lepu Biopharma Co. Ltd. Class H overvalued?
          According to Wall Street analysts Lepu Biopharma Co. Ltd. Class H’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Lepu Biopharma Co. Ltd. Class H pay dividends?
            Lepu Biopharma Co. Ltd. Class H does not currently pay dividends.
            What is Lepu Biopharma Co. Ltd. Class H’s EPS estimate?
            Lepu Biopharma Co. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Lepu Biopharma Co. Ltd. Class H have?
            Lepu Biopharma Co. Ltd. Class H has 1,804,439,800 shares outstanding.
              What happened to Lepu Biopharma Co. Ltd. Class H’s price movement after its last earnings report?
              Lepu Biopharma Co. Ltd. Class H reported an EPS of HK$0.022 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -6.035%.
                Which hedge fund is a major shareholder of Lepu Biopharma Co. Ltd. Class H?
                Currently, no hedge funds are holding shares in HK:2157

                Lepu Biopharma Co. Ltd. Class H Stock Smart Score

                Company Description

                Lepu Biopharma Co. Ltd. Class H

                Lepu Biopharma Co., Ltd., a biopharmaceutical company, focuses on developing oncology therapeutics with a pipeline designed with a range of oncology products in China. The company develops oncology drug candidates, including antibody-drug conjugates (ADC), oncolytic virus drugs, and immunotherapies. It develops immuno-oncology products, such as HX008 Anti-PD-1 mAb and LP002 Anti-PD-L1 mAb; ADC products, including MRG003 EGFR-targeted ADC, MRG002 HER2-targeted ADC, MRG001 CD20-targeted ADC, MRG004A TF-targeted ADC, and CMG901 CLDNI8.2-targeted ADC; CG0070 oncolytic virus; and other drug candidates, such as HX008+OH2, LP002+OH2, and HX008+LP002. The company was incorporated in 2018 and is headquartered in Shanghai, China.

                Lepu Biopharma Co. Ltd. Class H (2157) Earnings & Revenues

                Similar Stocks
                Company
                Price & Change
                Follow
                Ascletis Pharma, Inc.
                Keymed Biosciences, Inc.
                CARsgen Therapeutics Holdings Ltd.
                Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
                ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H

                Ownership Overview

                <0.01%99.23%
                Insiders
                <0.01%
                Mutual Funds
                ― Other Institutional Investors
                99.23% Public Companies and
                Individual Investors

                Options Prices

                Currently, No data available
                ---
                Popular Stocks
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis